French cosmetics giant L’Oréal has been granted a business licence in China to market its Episkin reconstructed skin model. It will market the technology through Shanghai Episkin Biotechnology.
China gives L’Oréal the Episkin all clear
French cosmetics giant L’Oréal has been granted a business licence in China to market its Episkin reconstructed skin model
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Year in review: 2025’s biggest beauty stories and headlines
Read moreA look at the beauty industry news stories and headlines that dominated in 2025, covering sweeping tariffs, job cuts, acquisitions, longevity and a hefty dose of controversy
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Body Care
Galderma, Rhode, Kering and more: The biggest beauty brand acquisitions in 2025 reshaping the industry
From Hailey Bieber’s Rhode being bought by e.l.f. Beauty to L’Oréal doubling its stake in Galderma and snapping up Kering Beauté, Cosmetics Business rounds up this year’s biggest beauty acquisitions and how they will impact the wider landscape
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.